Clinical Trials Logo

Bladder Carcinoma in Situ (CIS) clinical trials

View clinical trials related to Bladder Carcinoma in Situ (CIS).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04798703 Completed - Clinical trials for Bladder Carcinoma in Situ (CIS)

Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)

Start date: May 24, 2017
Phase: Phase 1
Study type: Interventional

Phase I exploratory, open-label, single arm, multicenter study to assess safety, tolerability and antitumor activity of ONCOFID-P-B™ therapy in adult patients with histologically confirmed diagnosis of bladder carcinoma in situ (CIS), who were unresponsive or intolerant to Bacillus Calmette-Guérin (BCG)-therapy. Patients are initially treated with 12 weekly intravesical instillations of ONCOFID-P-B™ (intensive treatment phase). Patients who achieve a complete response (CR) after the 12 weekly instillations entered the maintenance phase of the study, during which ONCOFID-P-B™ is furtherly administered once a month for 12 months.